NO990915L - Bruk av glukagonlignende peptid-1 (GLP-1) eller analoger for Õ fjerne katabolske endringer etter kirurgiske inngrep - Google Patents

Bruk av glukagonlignende peptid-1 (GLP-1) eller analoger for Õ fjerne katabolske endringer etter kirurgiske inngrep

Info

Publication number: NO990915L
Authority: NO; Norway
Prior art keywords: glp; analogues; glucagon; peptide; removal
Prior art date: 1996-08-30

Application number

NO990915A

Other languages

English (en)

Other versions

NO990915D0 (no

NO323338B1 (no

Inventor

Suad Efendic

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-30

Filing date

1999-02-25

Publication date

1999-04-13

1999-02-25 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1999-02-25 Publication of NO990915D0 publication Critical patent/NO990915D0/no

1999-04-13 Publication of NO990915L publication Critical patent/NO990915L/no

2007-04-02 Publication of NO323338B1 publication Critical patent/NO323338B1/no

Links

230000001925 catabolic effect Effects 0.000 title abstract 2
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 title 1
238000001356 surgical procedure Methods 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Immunology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19990915A 1996-08-30 1999-02-25 Anvendelse av et peptid for fremstilling av et preparat for behandling av pasienter som opplever hyperglykemi pa grunn av stress. NO323338B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2498296P	1996-08-30	1996-08-30
US08/916,991 US6006753A (en)	1996-08-30	1997-08-21	Use of GLP-1 or analogs to abolish catabolic changes after surgery
PCT/US1997/015042 WO1998008873A1 (en)	1996-08-30	1997-08-26	Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery

Publications (3)

Publication Number	Publication Date
NO990915D0 NO990915D0 (no)	1999-02-25
NO990915L true NO990915L (no)	1999-04-13
NO323338B1 NO323338B1 (no)	2007-04-02

Family

ID=26699130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19990915A NO323338B1 (no)	1996-08-30	1999-02-25	Anvendelse av et peptid for fremstilling av et preparat for behandling av pasienter som opplever hyperglykemi pa grunn av stress.

Country Status (20)

Country	Link
US (1)	US6006753A (no)
EP (2)	EP2181712A1 (no)
KR (1)	KR100365606B1 (no)
CN (1)	CN1235611A (no)
AT (1)	ATE418996T1 (no)
AU (1)	AU734140B2 (no)
BR (1)	BR9712084A (no)
CA (1)	CA2263802A1 (no)
DE (1)	DE69739189D1 (no)
DK (1)	DK0964873T3 (no)
EA (1)	EA003701B1 (no)
ES (1)	ES2318861T3 (no)
IL (1)	IL128740A (no)
MY (1)	MY121276A (no)
NO (1)	NO323338B1 (no)
NZ (1)	NZ334270A (no)
PL (1)	PL190991B1 (no)
UA (1)	UA58519C2 (no)
WO (1)	WO1998008873A1 (no)
YU (1)	YU10799A (no)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6852690B1 (en) *	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
US20020006899A1 (en) *	1998-10-06	2002-01-17	Pospisilik Andrew J.	Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE19616486C5 (de)	1996-04-25	2016-06-30	Royalty Pharma Collection Trust	Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) *	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) *	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
ES2649840T3 (es)	1998-08-06	2018-01-15	Mountain View Pharmaceuticals, Inc.	Uricasa tetramérica aislada
MY155270A (en) *	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
AU2003270960B2 (en) *	1998-09-24	2006-12-21	Eli Lilly And Company	Use of GLP-1 or Analogs in Treatment of Stroke
EP1652531A1 (en) *	1998-09-24	2006-05-03	Eli Lilly & Company	Use of GLP-1 or Analogues in Treatment of Stroke
US20030176357A1 (en) *	1998-10-06	2003-09-18	Pospisilik Andrew J.	Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US7259136B2 (en)	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
JP4949557B2 (ja) *	1999-03-17	2012-06-13	ノヴォノルディスクアー／エス	ペプチドのアシル化方法及び新規アシル化剤
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
ATE252601T1 (de)	1999-05-17	2003-11-15	Conjuchem Inc	Lang wirkende insulinotrope peptide
DE19926233C1 (de)	1999-06-10	2000-10-19	Probiodrug Ges Fuer Arzneim	Verfahren zur Herstellung von Thiazolidin
US9006175B2 (en) *	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EP2280020B1 (en)	1999-06-29	2016-02-17	MannKind Corporation	Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
DE19940130A1 (de) *	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US20060160740A1 (en) *	1999-10-21	2006-07-20	Suad Efendic	Use of GLP-1 or analogs in treatment of stroke
AU2001241168B2 (en) *	2000-03-17	2005-06-16	Ajinomoto Co., Inc.	Drugs for complications of diabetes and neuropathy and utilization thereof
EP2266665B1 (en) *	2000-03-31	2016-05-11	Royalty Pharma Collection Trust	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
CA2405709A1 (en)	2000-04-12	2001-10-25	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2001085256A2 (en)	2000-05-05	2001-11-15	Novo Nordisk A/S	Critical illness neuropathy
NZ519752A (en)	2000-10-20	2005-04-29	Amylin Pharmaceuticals Inc	Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US7132104B1 (en)	2000-10-27	2006-11-07	Probiodrug Ag	Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
CA2424475A1 (en) *	2000-10-27	2002-05-02	Probiodrug Ag	Method for the treatment of neurological and neuropsychological disorders
US6890905B2 (en)	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention
WO2002085406A1 (en) *	2001-04-24	2002-10-31	Restoragen, Inc.	Methods and compositions for treating conditions associated with insulin resistance
US20030130199A1 (en) *	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
DE10150203A1 (de) *	2001-10-12	2003-04-17	Probiodrug Ag	Peptidylketone als Inhibitoren der DPIV
US7368421B2 (en)	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
CN1363654A (zh) *	2001-07-19	2002-08-14	上海华谊生物技术有限公司	生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
US6642003B2 (en)	2001-08-02	2003-11-04	Cedars-Sinai Medical Center	Human glucose-dependent insulin-secreting cell line
US20040214762A1 (en) *	2001-08-16	2004-10-28	Hans-Ulrich Demuth	Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
US6844316B2 (en) *	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
CA2462543A1 (en) *	2001-10-01	2003-04-10	Eli Lilly And Company	Glucagon-like peptides (glp-1) and treatment of respiratory distress
ES2545090T3 (es)	2001-12-21	2015-09-08	Human Genome Sciences, Inc.	Proteínas de fusión de albúmina y GCSF
EP1463752A4 (en) *	2001-12-21	2005-07-13	Human Genome Sciences Inc	ALBUMIN FUSION PROTEINS
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
US20030199445A1 (en) *	2002-02-07	2003-10-23	Knudsen Lotte Bjerre	Use of GLP-1 compound for treatment of critically ill patients
WO2003066084A1 (en) *	2002-02-07	2003-08-14	Novo Nordisk A/S	Use of glp-1 compound for treatment of critically ill patients
CA2473340C (en) *	2002-02-20	2014-12-09	Eli Lilly And Company	Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
AU2003219922B2 (en)	2002-02-27	2009-09-10	Pharmain Corporation	Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) *	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) *	2004-04-23	2005-11-24	Bolotin Elijah M	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
ATE349435T1 (de) *	2002-02-28	2007-01-15	Prosidion Ltd	Dpiv-inhibitoren auf glutaminbasis
US7141240B2 (en) *	2002-03-12	2006-11-28	Cedars-Sinai Medical Center	Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
ES2300568T3 (es)	2002-03-20	2008-06-16	Mannkind Corporation	Aparato de inhalacion.
US20030232761A1 (en) *	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
US7291114B2 (en) *	2002-04-01	2007-11-06	Microlife Corporation	System and method of determining an individualized drug administration protocol
AU2003225277A1 (en) *	2002-05-02	2003-11-17	Robert Harris	Lipid removal from the body
AU2003243929B2 (en)	2002-07-04	2009-06-04	Zp Holding Spv K/S	GLP-1 and methods for treating diabetes
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US8372804B2 (en) *	2007-10-24	2013-02-12	Mannkind Corporation	Delivery of active agents
US20040033051A1 (en) *	2002-08-16	2004-02-19	Ip Kiril Kun Wan	Method and system for producing and displaying visual presentations which inhibit off-screen duplication
US20040058876A1 (en) *	2002-09-18	2004-03-25	Torsten Hoffmann	Secondary binding site of dipeptidyl peptidase IV (DP IV)
US20050176622A1 (en) *	2002-09-18	2005-08-11	Kerstin Kuhn-Wache	Secondary binding site of dipeptidyl peptidase IV (DPIV)
US7273921B2 (en)	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
KR20050083713A (ko) *	2002-10-02	2005-08-26	질랜드 파마 에이/에스	안정화된 엑센딘-4 화합물
US20040242566A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
ES2737835T3 (es)	2003-04-23	2020-01-16	Valeritas Inc	Bomba accionada hidráulicamente para la administración de medicamentos de larga duración
PT1620082E (pt) *	2003-05-05	2010-06-11	Probiodrug Ag	Utilização médica de inibidores de ciclases de glutaminilo e glutamato para o tratamento da doença de alzheimer e síndrome de down
ATE462432T1 (de) *	2003-05-05	2010-04-15	Probiodrug Ag	Glutaminylcyclase-hemmer
US7638638B2 (en)	2003-05-14	2009-12-29	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
CN101974090B (zh)	2003-06-12	2015-06-17	伊莱利利公司	Glp-1类似物融合蛋白质
ZA200602051B (en)	2003-08-13	2007-10-31	Takeda Pharmaceutical	4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP1699777B1 (en)	2003-09-08	2012-12-12	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP5707014B2 (ja) *	2003-10-15	2015-04-22	プロビオドルグエージー	グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用
US20050171112A1 (en) *	2003-11-03	2005-08-04	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
US20100099721A1 (en) *	2003-11-03	2010-04-22	Probiodrug Ag	Novel compounds for the treatment of neurological disorders
US20060286129A1 (en) *	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
AU2005210004B2 (en)	2004-02-05	2010-10-28	Probiodrug Ag	Novel inhibitors of glutaminyl cyclase
BRPI0507026A (pt) *	2004-02-09	2007-04-17	Human Genome Sciences Inc	proteìnas de fusão de albumina
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
UA85871C2 (uk)	2004-03-15	2009-03-10	Такеда Фармасьютікал Компані Лімітед	Інгібітори дипептидилпептидази
EA011168B1 (ru)	2004-04-23	2009-02-27	Конджачем Биотекнолоджис Инк.	Способ очистки конъюгатов альбумина
JP2008501714A (ja)	2004-06-04	2008-01-24	武田薬品工業株式会社	ジペプチジルペプチダーゼインヒビター
WO2006014425A1 (en) *	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Methods and devices for delivering glp-1 and uses thereof
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
BRPI0514263B8 (pt)	2004-08-20	2021-05-25	Mannkind Corp	método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
KR101306384B1 (ko)	2004-08-23	2013-09-09	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
JP2008524331A (ja)	2004-12-21	2008-07-10	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤
KR20070102694A (ko) *	2005-01-31	2007-10-19	아지노모토 가부시키가이샤	혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
DK1888103T3 (da) *	2005-04-11	2012-04-23	Amylin Pharmaceuticals Inc	Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
SG161247A1 (en)	2005-04-11	2010-05-27	Savient Pharmaceuticals Inc	Variant forms of urate oxidase and use thereof
CN101194016B (zh)	2005-04-11	2012-09-05	萨文特医药公司	尿酸氧化酶的变体形式及其用途
US8148123B2 (en)	2005-04-11	2012-04-03	Savient Pharmaceuticals, Inc.	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
PT1881850E (pt)	2005-05-13	2010-11-26	Lilly Co Eli	Compostos peguilados de glp-1
NZ565535A (en)	2005-06-30	2011-03-31	Ipsen Pharma Sas	GLP-1 pharmaceutical compositions
PE20070522A1 (es)	2005-09-14	2007-07-11	Takeda Pharmaceutical	2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
MX381952B (es)	2005-09-14	2025-03-13	Mannkind Corp	Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US20070060529A1 (en) *	2005-09-14	2007-03-15	Christopher Ronald J	Administration of dipeptidyl peptidase inhibitors
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2007053946A1 (en)	2005-11-09	2007-05-18	Conjuchem Biotechnologies Inc.	Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
EP3449946A3 (en)	2005-12-19	2020-11-04	PharmaIN Corporation	Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
JP5599975B2 (ja)	2006-02-22	2014-10-01	マンカインドコーポレイション	ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
KR101361376B1 (ko)	2006-03-30	2014-02-10	발레리타스 인코포레이티드	복합-카트리지 유체 전달 장치
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
SI2073810T1 (sl) *	2006-09-13	2011-12-30	Takeda Pharmaceutical	Uporaba 2-6(3-amino-piperidin-1-il)-3-metil-2,4-diokso-3,4-dihidro-2H-pirimidin -1-ilmetil-4-fluoro-benzonitrila za zdravljenje diabetesa, raka, avtoimunskih motenj in infekcije s HIV
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
JP2009019027A (ja)	2007-07-16	2009-01-29	Hanmi Pharmaceutical Co Ltd	アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
US7960336B2 (en)	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en)	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
DK2211842T3 (en) *	2007-10-24	2015-09-21	Mannkind Corp	An inhalable dry powder formulation COMPREHENSIVE GLP-1 FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DIABETES BY pulmonary delivery
WO2011163272A1 (en)	2010-06-21	2011-12-29	Mannkind Corporation	Dry powder drug delivery system and methods
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
KR101762089B1 (ko)	2008-06-13	2017-07-26	맨카인드 코포레이션	건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2421385T3 (es)	2008-06-20	2013-09-02	Mannkind Corp	Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US9526764B2 (en)	2008-10-17	2016-12-27	Sanofi-Aventis Deutschland Gmbh	Combination of an insulin and a GLP-1-agonist
US20100144140A1 (en) *	2008-12-10	2010-06-10	Novellus Systems, Inc.	Methods for depositing tungsten films having low resistivity for gapfill applications
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	GLP-1 analogues pharmaceutical compositions
US8538707B2 (en)	2009-03-11	2013-09-17	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
US8614185B2 (en) *	2009-05-04	2013-12-24	Centocor Ortho Biotech Inc.	Fusion proteins of alpha-MSH derivatives and Fc
WO2010129248A1 (en)	2009-05-06	2010-11-11	Centocor Ortho Biotech Inc.	Melanocortin receptor binding conjugates
MX2011013312A (es)	2009-06-12	2012-01-25	Mankind Corp	Microparticulas de dicetopiperazina con areas de superficie especificas definidas.
WO2010151823A1 (en)	2009-06-25	2010-12-29	Savient Pharmaceuticals Inc.	Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
EP2496295A1 (en)	2009-11-03	2012-09-12	MannKind Corporation	An apparatus and method for simulating inhalation efforts
HUE038147T2 (hu)	2009-11-13	2018-09-28	Sanofi Aventis Deutschland	GLP-1 agonistát, inzulint és metionint tartalmazó gyógyászati készítmény
WO2011058082A1 (de)	2009-11-13	2011-05-19	Sanofi-Aventis Deutschland Gmbh	Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
EP2555791B1 (en)	2010-04-09	2017-11-01	Sinai Health System	Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
US9089538B2 (en)	2010-04-27	2015-07-28	Zealand Pharma A/S	Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
CA2803646A1 (en)	2010-07-02	2012-01-05	Angiochem Inc.	Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
WO2012028172A1 (en)	2010-08-30	2012-03-08	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
ES2625858T3 (es)	2011-04-01	2017-07-20	Mannkind Corporation	Paquete de tipo blíster para cartuchos farmacéuticos
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN103945859A (zh)	2011-10-24	2014-07-23	曼金德公司	用于治疗疼痛的方法和组合物
US9259477B2 (en)	2011-11-03	2016-02-16	Zealand Pharma A/S	GLP-1 receptor agonist peptide gastrin conjugates
CN108057154B (zh)	2012-07-12	2021-04-16	曼金德公司	干粉药物输送系统和方法
UA117103C2 (uk)	2012-07-23	2018-06-25	Зіленд Фарма А/С	Сполука, яка має активність агоніста глюкагону
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2014144895A1 (en)	2013-03-15	2014-09-18	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
EP3021834A1 (en)	2013-07-18	2016-05-25	MannKind Corporation	Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
CN104371019B (zh)	2013-08-13	2019-09-10	鸿运华宁（杭州）生物医药有限公司	一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
AU2014336098B2 (en)	2013-10-17	2018-05-10	Boehringer Ingelheim International Gmbh	Acylated glucagon analogues
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
CA2932875A1 (en)	2014-01-09	2015-07-16	Sanofi	Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104310A1 (en)	2014-01-09	2015-07-16	Sanofi	Stabilized pharmaceutical formulations of insulin aspart
JP6641280B2 (ja)	2014-01-09	2020-02-05	サノフイＳａｎｏｆｉ	インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
WO2015148905A1 (en)	2014-03-28	2015-10-01	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
MX381640B (es)	2014-10-29	2025-03-04	Zealand Pharma As	Metodos y compuestos agonistas de gip.
HRP20230470T1 (hr)	2014-12-12	2023-07-21	Sanofi-Aventis Deutschland Gmbh	Formulacija fiksnog omjera inzulin glargin/liksisenatid
KR101825048B1 (ko)	2014-12-31	2018-02-05	주식회사 제넥신	GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
ES2833099T3 (es)	2015-02-11	2021-06-14	Gmax Biopharm Llc	Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US10336802B2 (en)	2015-04-16	2019-07-02	Zealand Pharma A/S	Acylated glucagon analogue
KR102502040B1 (ko)	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
CN118903385A (zh)	2017-08-24	2024-11-08	诺和诺德股份有限公司	Glp-1组合物及其用途
CN117003874A (zh)	2018-03-20	2023-11-07	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US12121566B2 (en)	2019-01-30	2024-10-22	Horizon Therapeutics Usa, Inc.	Methods for treating gout
CN112521501A (zh)	2019-09-18	2021-03-19	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
PE20230819A1 (es)	2020-02-18	2023-05-19	Novo Nordisk As	Composiciones y usos de glp-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5118666A (en) *	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5120712A (en) *	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
DE69129226T2 (de) *	1990-01-24	1998-07-30	Douglas I. Woodside Calif. Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
KR0154880B1 (ko) *	1992-06-15	1998-10-15	피터 알.셰어러	글루카곤-유사 펩티드 및 인슐리노트로핀 유도체
HU225496B1 (en) *	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use

1997
- 1997-08-21 US US08/916,991 patent/US6006753A/en not_active Expired - Lifetime
- 1997-08-26 EP EP08159135A patent/EP2181712A1/en not_active Withdrawn
- 1997-08-26 ES ES97938640T patent/ES2318861T3/es not_active Expired - Lifetime
- 1997-08-26 AU AU40926/97A patent/AU734140B2/en not_active Ceased
- 1997-08-26 YU YU10799A patent/YU10799A/sh unknown
- 1997-08-26 PL PL332003A patent/PL190991B1/pl not_active IP Right Cessation
- 1997-08-26 BR BR9712084A patent/BR9712084A/pt not_active Application Discontinuation
- 1997-08-26 DE DE69739189T patent/DE69739189D1/de not_active Expired - Lifetime
- 1997-08-26 DK DK97938640T patent/DK0964873T3/da active
- 1997-08-26 KR KR10-1999-7001611A patent/KR100365606B1/ko not_active IP Right Cessation
- 1997-08-26 EP EP97938640A patent/EP0964873B1/en not_active Expired - Lifetime
- 1997-08-26 AT AT97938640T patent/ATE418996T1/de not_active IP Right Cessation
- 1997-08-26 CA CA002263802A patent/CA2263802A1/en not_active Abandoned
- 1997-08-26 CN CN97199222A patent/CN1235611A/zh active Pending
- 1997-08-26 EA EA199900169A patent/EA003701B1/ru not_active IP Right Cessation
- 1997-08-26 WO PCT/US1997/015042 patent/WO1998008873A1/en active IP Right Grant
- 1997-08-26 IL IL128740A patent/IL128740A/en not_active IP Right Cessation
- 1997-08-26 UA UA99021151A patent/UA58519C2/uk unknown
- 1997-08-26 NZ NZ334270A patent/NZ334270A/xx unknown
- 1997-08-28 MY MYPI97003977A patent/MY121276A/en unknown
1999
- 1999-02-25 NO NO19990915A patent/NO323338B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP2181712A1 (en)	2010-05-05
MY121276A (en)	2006-01-28
NO990915D0 (no)	1999-02-25
ES2318861T3 (es)	2009-05-01
CN1235611A (zh)	1999-11-17
NZ334270A (en)	2000-07-28
IL128740A0 (en)	2000-01-31
US6006753A (en)	1999-12-28
EP0964873A4 (en)	2002-07-03
BR9712084A (pt)	1999-08-24
WO1998008873A1 (en)	1998-03-05
AU4092697A (en)	1998-03-19
PL332003A1 (en)	1999-08-16
EA003701B1 (ru)	2003-08-28
PL190991B1 (pl)	2006-02-28
CA2263802A1 (en)	1998-03-05
EP0964873B1 (en)	2008-12-31
DK0964873T3 (da)	2009-03-16
UA58519C2 (uk)	2003-08-15
KR20000035895A (ko)	2000-06-26
NO323338B1 (no)	2007-04-02
KR100365606B1 (ko)	2003-02-07
EA199900169A1 (ru)	1999-08-26
IL128740A (en)	2007-08-19
YU10799A (sh)	2003-04-30
DE69739189D1 (de)	2009-02-12
EP0964873A1 (en)	1999-12-22
ATE418996T1 (de)	2009-01-15
AU734140B2 (en)	2001-06-07

Publication	Publication Date	Title
NO990915L (no)	1999-04-13	Bruk av glukagonlignende peptid-1 (GLP-1) eller analoger for Õ fjerne katabolske endringer etter kirurgiske inngrep
SE9802080D0 (sv)	1998-06-11	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1695983A3 (en)	2007-02-21	Glucagon-like peptide-1 analogs
HK1047887B (zh)	2005-05-13	氨基酸的四氫噻唑-或四氫化吡咯衍生物作為抗高血糖劑的應用
ATE394423T1 (de)	2008-05-15	Analoge des glucagon ähnlichen peptides-1 (glp-1)
AR019818A1 (es)	2002-03-20	Un inmunoconjugado de miostatina.
FI912348A0 (fi)	1991-05-14	Stabiliserad fgf sammansaettning.
ATE168185T1 (de)	1998-07-15	Zielfernrohr
FI871179A0 (fi)	1987-03-18	Bitumen komposition och dess anvaendning som i kallt tillstaond anbringbar sjaelvhaeftande blandning.
JPS5291852A (en)	1977-08-02	Azetidinones
FR2684390B1 (fr)	1994-10-21	Elimination de couches d'oxyde de moulages en titane, par utilisation d'un agent de desoxydation alcalino-terreux.
FR2703584B1 (fr)	1995-06-09	Viseur de coupes tibiales.
AU3850100A (en)	2000-09-28	Placing unit for a human being
SE9303068D0 (sv)	1993-09-21	New use
EP1359159A3 (en)	2004-07-21	Analogues of GLP-1
DE69902843D1 (de)	2002-10-17	Flexibler, mehrschichtiger Kühlmittelförderschlauch
FI931601L (fi)	1993-04-08	1'aminospiro(isokinolin-4(1h), 3'-pyrrolidin)-1,2',3,5'(2h)-tetroner och analoger daerav anvaendbara som aldosreduktasinhibitorer
ATE374920T1 (de)	2007-10-15	Jagdpatronenhülse mit einer schutzschicht
MX9207461A (es)	1993-06-01	Soluciones de poli(sulfuro de arileno), procedimientos para su preparacion y su utilizacion.
ES536767A0 (es)	1985-10-16	Mejoras introducidas en el objeto de la patente principal n 450.908, concedida el 25 de mayo de 1977 por: perfeccionamientos en equipos filtrantes para piscinas
DE3465845D1 (en)	1987-10-08	Circuit arrangement for starting and operating a gas discharge laser
NO913502D0 (no)	1991-09-05	Kompositt for anvendelse som hoeyenergi-sprengstoff eller drivmiddel.
NO160692C (no)	1989-05-24	Lysbeskyttelsesfilter, saerlig for sveisebeskyttelsesskjermer eller sveisebeskyttelsesbriller.
FI903977A0 (fi)	1990-08-10	Komposition foer framstaellning av uretan- och isocyanurat-uretanskumplaster och foerfarande foer framstaellning av en hydroxylhaltig komponent som anvaends foer framstaellning av denna komposition.
RU96124646A (ru)	1999-02-10	Композиция для защиты металлов от кислотной коррозии

Legal Events

Date	Code	Title	Description
2010-03-22	MM1K	Lapsed by not paying the annual fees